Genetically engineered tetravalent single-chain Fv of the pancarcinoma monoclonal antibody CC49: Improved biodistribution and potential for therapeutic application

Cancer Research

Volumn 60, Issue 24, 2000, Pages 6964-6971

  Goel, A ^a   Colcher, D ^a   Baranowska Kortylewiez, J ^a   Augustine, S ^a   Booth, B J M ^a   Pavlinkova, G ^a   Batra, S K ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL OXIDASE; GLYCOPROTEIN; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CC 49; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CANCER THERAPY; COLON CARCINOMA; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG HALF LIFE; FEMALE; GENE EXPRESSION REGULATION; GENETIC ENGINEERING; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; RADIATION DOSE DISTRIBUTION; RADIATION EXPOSURE; SOLID TUMOR;

ALCOHOL OXIDOREDUCTASES; AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COLONIC NEOPLASMS; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FEMALE; GENETIC ENGINEERING; GENETIC VECTORS; IMMUNOGLOBULIN G; MICE; MICE, NUDE; MODELS, BIOLOGICAL; MOLECULAR SEQUENCE DATA; NEOPLASM TRANSPLANTATION; PICHIA; PROMOTER REGIONS (GENETICS); PROTEIN BINDING; RADIOIMMUNOASSAY; SEQUENCE HOMOLOGY, AMINO ACID; SURFACE PLASMON RESONANCE; TIME FACTORS; TISSUE DISTRIBUTION;

EID: 0034671309     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (71)

1. Clinical issues in antibody design
2. Recent progress in radioimmunotherapy for cancer
3. 131I-CC49 in colorectal cancer
4. Prediction of hematologic toxicity after radioimmunotherapy with (131)I-labeled anticarcinoembryonic antigen monoclonal antibodies
5. Radiolabeled antibody therapy of B-cell lymphomas
6. Dosimetry and dose-response relationships in newly diagnosed patients with malignant gliomas treated with iodine-131-labeled anti-tenascin monoclonal antibody 81C6 therapy
7. Monoclonal antibodies in diagnosis and therapy
8. Effects of genetic engineering on the pharmacokinetics of antibodies
9. Transport of molecules across tumor vasculature
10. New protein engineering approaches to multivalent and bispecific antibody fragments
11. Recombinant antibody constructs in cancer therapy
12. Single-chain antigen-binding proteins
13. A recombinant immunotoxin containing a disulfide-stabilized Fv fragment
14. In vivo tumor targeting of a recombinant single-chain antigen-binding protein
15. Construction, binding properties, metabolism, and tumor targeting of a single-chain Fv derived from the pancarcinoma monoclonal antibody CC49
16. Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms
17. Highly specific in vivo tumor targeting by monovalent and divalent forms of 741F8 anti-cerbB-2 single-chain Fv
18. Pharmacokinetics and biodistribution of engineered single-chain antibody constructs of MAb CC49 in colon carcinoma xenografts
19. Clinical evidence of efficient tumor targeting based on single-chain Fv antibody selected from a combinatorial library
20. Single chain antigen binding protein (sFv CC49): First human studies in colorectal carcinoma metastatic to liver
21. Radioimmunotherapy of human colon cancer xenografts using a dimeric single-chain Fv antibody construct
22. Analysis of a human tumor-associated glycoprotein (TAG-72) identified by monoclonal antibody B72.3
23. Tumor localization of anti-CEA single-chain Fvs: Improved targeting by non-covalent dimers
24. Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu
25. Binding characteristics and tumor targeting of a covalently linked divalent CC49 single-chain antibody
26. Single-chain antibody streptavidin fusions: Tetrameric bifunctional scFv-complexes with biotin binding activity and enhanced affinity to antigen
27. Tetravalent miniantibodies with high avidity assembling in Escherichia coli
28. Multivalent antibody fragments with high functional affinity for a tumor-associated carbohydrate antigen
29. Triabodies: Single chain Fv fragments without a linker form trivalent trimers
30. Single-chain Fv fragments of anti-neuraminidase antibody NC10 containing five- and ten-residue linkers form dimers and with zero-residue linker a trimer
31. A recombinant human scFv anti-Rh(D) antibody with multiple valences using a C-terminal fragment of C4-binding protein
32. Design and production of novel tetravalent bispecific antibodies
33. Generation and characterization of a single gene-encoded single-chain-tetravalent antitumor antibody
34. Di-, tri- and tetrameric single chain Fv antibody fragments against human CD19: Effect of valency on cell binding
35. Novel tetravalent and bispecific IgG-like antibody molecules combining single-chain diabodies with the immunoglobulin γ1 Fc or CH3 region
36. Preparation, characterization, and in vivo biodistribution properties of synthetically cross-linked multivalent antitumor antibody fragments
37. Improved tumor targeting with chemically cross-linked recombinant antibody fragments
38. Preparation of a trivalent antigen-binding construct using polyoxime chemistry: Improved biodistribution and potential for therapeutic application
39. Conformational stability, folding, and ligand-binding affinity of single-chain Fv immunoglobulin fragments expressed in Escherichia coli
40. Divalent form of CC49 single-chain antibody constructs in Pichia pastoris: Expression, purification and characterization
41. Protein measurement by Folin phenol
42. Cleavage of structural proteins during the assembly of the head of bacteriophage T4
43. Radiolocalization of human mammary tumors in athymic mice by a monoclonal antibody
44. Single-chain antibodies in pancreatic cancer
45. Kinetic analysis of monoclonal antibody-antigen interactions with a new biosensor based analytical system
46. Human colonic adenocarcinoma cells. I. Establishment and description of a new line
47. Targeting strategies for cancer radiotherapy
48. Clinical comparison of radiolocalization of two monoclonal antibodies (mAbs) against the TAG-72 antigen
49. Phase I study of intravenous Lu-labeled CC49 murine monoclonal antibody in patients with advanced adenocarcinoma
50. 188Re-labeled trisuccin-HuCC49 and trisuccin- HuCC49-deltaCh2 conjugates in athymic nude mice bearing intraperitoneal colon cancer xenografts
51. 131I-labeled CC49 for therapy in a colon cancer xenograft model
52. Charge-modified single chain antibody constructs of monoclonal antibody CC49: Generation, characterization, pharmacokinetics, and biodistribution analysis
53. Spontaneous assembly of bivalent single chain antibody fragments in Escherichia coli
54. Multivalent Fvs: Characterization of single-chain Fv oligomers and preparation of a bispecific Fv
55. Monoclonal antibody homodimers: Enhanced antitumor activity in nude mice
56. Affinity enhancement of a recombinant antibody: Formation of complexes with multiple valency by a single-chain Fv fragment-core streptavidin fusion
57. Model and simulation of multivalent binding to fixed ligands
58. Binding parameters of antibodies reacting with multivalent antigens: Functional affinity or pseudo-affinity
59. Pharmacokinetics and biodistribution of a light chain shuffled CC49 single-chain Fv antibody construct
60. The influence of polyvalency on the binding properties of antibodies
61. Effect of bivalent interaction upon apparent antibody affinity: Experimental confirmation of theory using fluorescence photo-bleaching and implications for antibody binding assays
62. Minibody: A novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain Fv-CH3) which exhibits rapid, high-level targeting of xenografts
63. IgM secretory tailpiece drives multimerization of bivalent scFv fragments in eukaryotic cells
64. Increased binding affinity and valence of recombinant antibody fragments lead to improved targeting of tumoral angiogenesis
65. Human monoclonal antibody homodimers. Effect of valency on in vitro and in vivo antibacterial activity
66. Homodimerization of tumor-reactive monoclonal antibodies markedly increases their ability to induce growth arrest or apoptosis of tumor cells
67. Dosimetric evaluation and radioimmunotherapy of anti-tumour multivalent Fab' fragments
68. Radioimmunolocalization of human carcinoma xenografts with B72.3 second generation monoclonal antibodies
69. Therapeutic advantage of high-affinity anticarcinoma radioimmunoconjugates
70. The pharmacology of monoclonal antibodies
71. Transport of fluid and macromolecules in tumors. I. Role of interstitial pressure and convection